Krsnaa Diagnostics · tone and specificity signals across the available quarters.
Language signals
We are structurally advantaged platform with diversified revenue streams, contracted growth from long-term PPPs and accelerating high margin retail. This is a business designed not just to grow with the market but to take share from it consistently and profitably.
The Rajasthan tender, the revenue per test would be more or less in the similar ranges but as the project matures we expect the revenue per patient also to increase.
On the working capital we've collected our money from various authorities. The payments have started flowing in. The retail business is also ramping up with most of these being cash paying customers, which gives us a good position to scale with the current network.
We have maintained our unblemished record of virtually zero bad debts since inception. The timing delays are administrative in nature, not a credit risk issue.
We don't recklessly pursue PPPs... the simple reason being we don't recklessly participate in PPPs that don't create long-term value. That is why Krishna is able to be a successful company in the PPP space whereas there are other players who have not been successful enough.
While yes we had aspirations to grow at a higher [rate]... whilst there were also certain reasons. Some of the reasons could be attributed to delays. Just to give you a reference of Maharashtra, the Maharashtra project itself had certain delays getting government sites on time.
The retail has the potential to become a very meaningful long-term growth and cash flow driver for Krishna. Our strategic investment in Apulki Healthcare positions Krishna within the oncology and cardiac care ecosystems which we believe represent a very significant long-term healthcare opportunity in India.